missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Anthrax Edema Factor Synthetic Peptide
Description
Anthrax Edema Factor Synthetic Peptide, PEP-0213, from Invitrogen.
Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. EF is a calmodulin and Ca++-dependent adenylate cyclase responsible for the edema seen in the disease. It is thought to benefit the B. anthracis bacteria by inhibiting cells of the host immune system.
Spécifications
Spécifications
| Species | Bacteria |
| Purification Method | purified |
| Common Name | Anthrax Edema Factor |
| Concentration | 200 μg/mL |
| Content And Storage | -20°C |
| Description | Synthetic Peptide |
| Format | Liquid |
| Formulation | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| For Use With (Application) | Blocking Assay, Control |
| Lyophilized | No |
| Afficher plus de résultats |